About Contact Us Careers
Sign In

Human Microbiome Market Size & Share, by Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs), Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases), Organism Type (Aerobic Organisms, Obligate & Facultative Anaerobes, Genetically Engineered Strains, BSL-2 & Spore-Forming Species), Application (Therapeutics, Diagnostics) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

  • Report ID: 4062
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Human Microbiome Market size was over USD 445.92 million in 2024 and is projected to cross USD 11.73 billion by the end of 2037, witnessing more than 32.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of human microbiome is estimated at USD 561.5 million. The rising cases of lifestyle-related diseases such as diabetes and the increasing investment in biological drug development across the globe are expected to propel market growth. It is found that dysbiosis, or abnormalities in the microbiome, can lead to the development of several lifestyle disorders.

The rise in research activities about the impact of the microbiome on health and the development of microbiome-based goods and services is predicted to create the potential for market expansion over the estimated period. Additionally, increasing technological advancements are further believed to fuel the growth of the human microbiome market. For instance, it is now simpler and less expensive to investigate the microbiome owing to developments in DNA sequencing technology.

Human Microbiome Market Overview
Get more information on this report: Request Free Sample PDF

Human Microbiome Sector: Growth Drivers and Challenges

Growth Drivers

  • Growing Incidence of Respiratory Diseases – Ongoing studies state that the lung microbiome increases the proneness to respiratory diseases and influences responses to treatment. Hence, the surge in investment in comprehending the lung microbiome to develop both diagnostic and prognostic biomarkers for respiratory diseases in clinical settings will drive market growth.
  • Increasing Prevalence of Gastrointestinal Disorders – According to a study, globally around 35% of people lived with functional gastrointestinal disorders in 2021. It is expected that with the growing cases of gastrointestinal disorders and digestive health, including diarrhea, constipation, and bowel incontinence, the rising influence of the human gut microbiome in both health and disease is slated to expand the market in the upcoming years.
  • Rising Health Spending and Extensive Research About Human Microbiome – The increasing involvement of the human microbiome in human metabolism, nutrition, physiology, and immune function is responsible for several ongoing studies on the human microbiome and its function. The rising need to eliminate the growing healthcare expenditure worldwide by improving the gut microbiota and the human microbiome is poised to drive market expansion.

Challenges

  • Strict Government Rules & Regulations- The emerging regulations by the government for the market are one of the major factors counted to slow down the market growth. For instance, probiotics are regarded as dietary supplements and no microbiome-based probiotics have received FDA approval as live biotherapeutic products (LBP).
  • Lack of Knowledge about Human Microbiome Products
  • Absence of Sufficient Research on the Human Microbiome

Human Microbiome Market: Key Insights

Base Year

2024

Forecast Year

2025-2037

CAGR

32.2%

Base Year Market Size (2024)

USD 445.92 million

Forecast Year Market Size (2037)

USD 11.73 billion

Regional Scope
  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Human Microbiome Segmentation

Product (Probiotics, Prebiotics, Diagnostic Tests, Drugs)

The probiotics segment is set to gain the largest market share of 40% by the year 2037. The increasing prevalence of digestive diseases across the globe is driving the demand for probiotics as some probiotics can improve the immune system, reduce inflammation, and may even lower cholesterol. According to statistics, more than 35% of people around the world experience persistent digestive issues. It is assessed that live bacteria and yeasts called probiotics are beneficial to health, particularly the digestive system, and have been proven to be successful in treating common symptoms, including bloating, stomach pain, and diarrhea. 

The drugs segment is counted to pool in the highest revenue in the given period owing to the rising investment in the field of live biotherapeutics which is envisaged to develop pharmacologic treatments for a range of diseases.

Disease Type (Infectious Disease, Obesity, Diabetes, Gastrointestinal Diseases, Cancer, Cardiovascular Diseases)

The gastrointestinal diseases segment is speculated to garner a significant growth rate of around 46% through 2037, as the development and treatment of gastrointestinal illnesses are significantly influenced by the human microbiome. Gut health could be improved and the risk of gastrointestinal disorders could be decreased with probiotics, prebiotics, and other microbiome-targeted medicines. This, as a result, is anticipated to create numerous opportunities for the growth of the segment in the coming years.

Our in-depth analysis of the global market includes the following segments:

         Product

  • Probiotics

  • Prebiotics

  • Diagnostic Tests

  • Drugs

         Disease Type

  • Infectious Disease

  • Obesity

  • Diabetes

  • Gastrointestinal Diseases

  • Cancer

  • Cardiovascular Diseases

        Organism Type

  • Aerobic Organisms

  • Obligate & Facultative Anaerobes

  • Genetically Engineered Strains

  • BSL-2 & Spore-Forming Species

         Application

  • Therapeutics

  • Diagnostics

        Technology

  • Genomics

  • Proteomics

  • Metabolomics

 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Human Microbiome Industry - Regional Synopsis

North American Market Forecast

The human microbiome market in North America is poised to account for the largest share of 35% by the end of 2037, driven by rising pet adoption. The rising frequency of lifestyle illnesses in developed countries such as the United States is boosting the demand for microbiome-related goods and services, as people look for ways to enhance their gut health and overall health outcomes. According to data, the prevalence of age- and lifestyle-related diseases in the US is forecasted to rise by more than 15% over the next 20 years. Hence, the human microbiome market in North America will expand during the forecast period with an increase in government initiatives to enable the study of microbial communities to improve understanding of the microbiota and support human health in the region.

Europe Market Forecast

The Europe human microbiome market is estimated to be the second largest regional market with a share of about 25% by the end of 2037. The growth in research & development (R&D) activities for new applications of the human microbiome and the long-term vision of developing a life science ecosystem with the rising investments for biomedical research is predicted to expand the market in the region.

Research Nester
Human Microbiome Market Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Human Microbiome Landscape

    • Seres Therapeutics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Evelo Biosciences, Inc.
    • Synlogic, Inc.
    • Second Genome Inc.
    • Synthetic Biologics, Inc.
    • YSOPIA Bioscience
    • 4D Pharma plc
    • DuPont de Nemours, Inc.
    • BiomX Inc.
    • Sun Genomics, Inc.
    • Viome Life Sciences, Inc.

In the News

  • Viome Life Sciences, Inc. launched the CancerDetect test for oral and throat cancer. Further, this test also fills a market gap by offering advanced, early detection at the point when it is most controllable and is the first to find biomarkers for early-stage oral and throat cancers.
  • Seres Therapeutics, Inc. teamed up with Bacthera to produce SER-109, for reoccurring Clostridium difficile infection (rCDI). Further, the collaboration enhanced the initial commercial manufacturing supply chain, which will strengthen SER-109's commercial production capacities and provide supply support.

 

 

Author Credits:  Radhika Pawar


  • Report ID: 4062
  • Published Date: Oct 10, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of human microbiome is estimated at USD 561.5 million.

The human microbiome market size was over USD 445.92 million in 2024 and is projected to cross USD 11.73 billion by the end of 2037, witnessing more than 32.2% CAGR during the forecast period i.e., between 2025-2037. Growing prevalence of the human microbiome in health and disease and increasing research on its major impact on human physiology, metabolic and immune functions will boost the market growth.

North America is poised to account for the largest share of 35% by 2037, driven by rising pet adoption in the region.

The major players in the market include Seres Therapeutics, Inc., Evelo Biosciences, Inc., Synlogic, Inc., Second Genome Inc., Synthetic Biologics, Inc., YSOPIA Bioscience, 4D Pharma plc, DuPont de Nemours, Inc., BiomX Inc., Sun Genomics, Inc., Viome Life Sciences, Inc.
Human Microbiome Market Report Scope

Copyright © 2024 Research Nester. All Rights Reserved

logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample